Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031614 | 0.92 | BRAF (0.46) | BRAF | |
| SCHEMBL4034915 | 0.92 | BRAF (0.47) | BRAF | |
| Hydrochloric Acid SCHEMBL4034747 | 0.91 | BRAF (0.46) | BRAF | |
| SCHEMBL4032448 | 0.87 | BRAF (0.45) | BRAF | |
| SCHEMBL4036624 | 0.86 | BRAF (0.47) | BRAF | |
| SCHEMBL302551 | 0.83 | BRAF (0.47) | BRAF | |
| SCHEMBL4034309 | 0.82 | BRAF (0.49) | BRAF | |
| SCHEMBL4031982 | 0.82 | BRAF (0.43) | BRAF | |
| SCHEMBL4032046 | 0.80 | BRAF (0.47) | BRAF | |
| SCHEMBL13848724 | 0.80 | BRAF (0.40) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4850824-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |